Navigation Links
Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology
Date:1/10/2011

CAMBRIDGE, Mass. and NEW YORK, Jan. 10, 2011 /PRNewswire/ -- Resolvyx Pharmaceuticals (Resolvyx) and Celtic Therapeutics Holdings L.P. (Celtic Therapeutics), a successor firm to Celtic Pharma, announced today that they have entered into a final agreement under which Celtic Therapeutics has acquired and licensed worldwide rights related to Resolvyx's RX-10045, a late-stage program for the treatment of dry eye syndrome and other ophthalmic conditions.  Terms of the deal include upfront consideration, near-term milestone payments, and funding for 100% of future development costs. Resolvyx and Celtic Therapeutics will share proceeds from the future divestiture of RX-10045, including up-front payments, royalties or other revenues.

Under the terms of the agreement, Celtic Therapeutics will acquire and license rights to Resolvyx's RX-10045, in all ophthalmic indications. RX-10045 is scheduled to enter a Phase III randomized, placebo-controlled, multi-center study in 2011. As part of the agreement, Celtic Therapeutics may also license rights to and develop a second Resolvyx compound in a topical formulation for ophthalmic indications.

Resolvins are a recently discovered family of naturally-occurring, small molecule lipid mediators that can be targeted to treat a wide range of diseases. Resolvins are shown to be highly potent and efficacious across a broad range of pre-clinical models of asthma, atherosclerosis, rheumatoid arthritis, inflammatory bowel disease, dry eye and retinal disease, among others. Resolvyx will continue to develop Resolvins for non-ophthalmic indications.

Dry eye, one of the most common problems treated by ophthalmologists, and a $1.7 billion global market today, is a chronic, multifactorial disease involving inflammation of the tear ducts and ocular surfaces that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surfaces. RX-10045, a resolvin
'/>"/>

SOURCE Celtic Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Celtic Therapeutics and Resolvyx Pharmaceuticals Announce an Alliance in Ophthalmology
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... TEANECK, N.J. , May 21, 2013 /PRNewswire-iReach/ ... 17-19 in NJ has attracted the greatest number ... reports its President, Mark Alexay ... "But suddenly everyone plans to attend this year.  The show,s still ... of different companies.  This is a big surprise ...
(Date:5/21/2013)... 2013  IsoRay, Inc. (AMEX: ISR ), ... into an exclusive international distribution agreement with IASIS Medical ... Greece . IsoRay is a medical ... radioisotope applications for brain cancer, lung cancer, head and ... IASIS Medical is ideally suited to support ...
(Date:5/21/2013)... 2013  The North Shore-LIJ Health System is expanding ... compliance at North Shore University Hospital in ... rooms at Forest Hills (NY) ... The new pilot program strengthens patient safety by providing ... the first time in the US that remote video ...
Breaking Medicine Technology:Emerging Pharma at ChemOutsourcing 2013 in Record Numbers for Upcoming September Show 2IsoRay Announces A New International Distributor For Greece 2IsoRay Announces A New International Distributor For Greece 3North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 2North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 3North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 4
(Date:5/21/2013)... 2013) Prostaglandin analogues (PGAs), drugs which lower intraocular ... people with glaucoma, but their use is not without ... dryness, changes in eye color and other side effects. ... also cause upper and lower eyelid drooping and other ... described in PLOS ONE . , Researchers from ...
(Date:5/21/2013)... May 21, 2013 Parker Waichman LLP, ... of victims injured by defective medical devices, is addressing ... Joint Surgery on May 15, 2013. The study found ... identify complications that occur in patients with metal-on-metal hip ... ( http://www.jbjs.org/article.aspx?articleid=1684770 ) , “We’ve known ...
(Date:5/21/2013)... HealthSmart continues to grow through strategic acquisitions ... the hiring of new talent in several areas, including ... that Dawn Powell has joined the organization effective April ... Account Management in the Central Region and is based ... extensive client management, employee benefits, and product development experience, ...
(Date:5/21/2013)... 21 May 2013, Paris, France: One-year results from SOURCE ... valve implantation (TAVI) registries to-date reported today at ... practice, with high rates of device success for all ... SOURCE XT Post-Approval Study followed up 2688 consecutively enrolled ... Sapien XT heart valve at 93 centres in 17 ...
(Date:5/21/2013)... AZ (PRWEB) May 21, 2013 ... and inventors who want to develop their ideas ... summer program. , The university is recruiting ... revolutionary new “formation space” that provides early-stage entrepreneurs ... While AREA48 is open to anyone, ASU is ...
Breaking Medicine News(10 mins):Health News:Glaucoma drug can cause droopy eyelids 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:New Talent Joins the HealthSmart Account Management Team 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4
... Long Island Patient Information eXchange (LIPIX) went live with ... accessing LIPIX online systems. LIPIX realizes the value ... through its HIE, but also understands that it is ... that the information will be protected. "As more ...
... But weight training can boost strength in other ways, researchers ... did not build muscle mass in octogenarian women but still ... conducted by Ball State University in Indiana finds. , ... three times a week for three months on a machine ...
... to Self-Report Suspected MeaslesHARRISBURG, Pa., April 3 The Pennsylvania ... Department and UPMC,s Children,s Hospital of Pittsburgh today confirmed they ... Hospital. Exposures to measles may have occurred in the Children,s ... , March 10, at ...
... /PRNewswire-FirstCall/ - The Westaim Corporation today announced that ... to maximize the value of the Company,s strong ... strategy, Westaim has entered into a management services ... an affiliate of Goodwood Inc., to manage the ...
... 3 eDiets.com, Inc. (Nasdaq: DIET ... healthy lifestyle solutions, today announced that it received a notice ... of the Company,s listed securities has fallen below $35 million, ... Market, in compliance with NASDAQ Marketplace Rule 4310(c)(3)(B). The ...
... the toxin in leg bones are tied to poorer scores on ... higher levels of environmental lead earlier in the life span may ... a new study finds. , The Harvard study shows that women ... blood (indicating a recent exposure to the metal) or bones (an ...
Cached Medicine News:Health News:LIPIX Protects Access to Electronic Health Information With the Anakam Identity Suite(R) 2Health News:LIPIX Protects Access to Electronic Health Information With the Anakam Identity Suite(R) 3Health News:Muscle Mass Won't Grow in Women Over 80 2Health News:Pennsylvania State Department of Health and Allegheny County Health Department Confirm Four Cases of Measles in Southwest Region 2Health News:Pennsylvania State Department of Health and Allegheny County Health Department Confirm Four Cases of Measles in Southwest Region 3Health News:Westaim enters into Management Services Agreement 2Health News:eDiets.com(R) Receives NASDAQ Notice Regarding Market Value of Listed Securities 2Health News:eDiets.com(R) Receives NASDAQ Notice Regarding Market Value of Listed Securities 3Health News:Accumulated Lead May Affect Older Women's Brains 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: